Gemma Elizabeth Shields1, Deborah Buck2, Jamie Elvidge3, Karen Petra Hayhurst4, Linda Mary Davies1. 1. Centre for Health Economics, Division of Population Health, University of Manchester. 2. Personal and Social Services Research Unit, University of Manchester. 3. National Institute for Health and Care Excellence, United Kingdom. 4. Division of Psychology and Mental Health, University of Manchester, Manchester.
Abstract
OBJECTIVES: This review aims to assess the cost-effectiveness of psychological interventions for schizophrenia/bipolar disorder (BD), to determine the robustness of current evidence and identify gaps in the available evidence. METHODS: Electronic searches (PsycINFO, MEDLINE, Embase) identified economic evaluations relating incremental cost to outcomes in the form of an incremental cost-effectiveness ratio published in English since 2000. Searches were concluded in November 2018. Inclusion criteria were: adults with schizophrenia/BD; any psychological/psychosocial intervention (e.g., psychological therapy and integrated/collaborative care); probability of cost-effectiveness at explicitly defined thresholds reported. Comparators could be routine practice, no intervention, or alternative psychological therapies. Screening, data extraction, and critical appraisal were performed using pre-specified criteria and forms. Results were summarized qualitatively. The protocol was registered on the PROSPERO database (CRD42017056579). RESULTS: Of 3,864 studies identified, 12 met the criteria for data extraction. All were integrated clinical and economic randomized controlled trials. The most common intervention was cognitive behavioral therapy (CBT, 6/12 studies). The most common measure of health benefit was the quality-adjusted life-year (6/12). Follow-up ranged from 6 months to 5 years. Interventions were found to be cost-effective in most studies (9/12): the probability of cost-effectiveness ranged from 35-99.5 percent. All studies had limitations and demonstrated uncertainty (particularly related to incremental costs). CONCLUSIONS: Most studies concluded psychological interventions for schizophrenia/BD are cost-effective, including CBT, although there was notable uncertainty. Heterogeneity across studies makes it difficult to reach strong conclusions. There is a particular need for more evidence in the population with BD and for longer-term evidence across both populations.
OBJECTIVES: This review aims to assess the cost-effectiveness of psychological interventions for schizophrenia/bipolar disorder (BD), to determine the robustness of current evidence and identify gaps in the available evidence. METHODS: Electronic searches (PsycINFO, MEDLINE, Embase) identified economic evaluations relating incremental cost to outcomes in the form of an incremental cost-effectiveness ratio published in English since 2000. Searches were concluded in November 2018. Inclusion criteria were: adults with schizophrenia/BD; any psychological/psychosocial intervention (e.g., psychological therapy and integrated/collaborative care); probability of cost-effectiveness at explicitly defined thresholds reported. Comparators could be routine practice, no intervention, or alternative psychological therapies. Screening, data extraction, and critical appraisal were performed using pre-specified criteria and forms. Results were summarized qualitatively. The protocol was registered on the PROSPERO database (CRD42017056579). RESULTS: Of 3,864 studies identified, 12 met the criteria for data extraction. All were integrated clinical and economic randomized controlled trials. The most common intervention was cognitive behavioral therapy (CBT, 6/12 studies). The most common measure of health benefit was the quality-adjusted life-year (6/12). Follow-up ranged from 6 months to 5 years. Interventions were found to be cost-effective in most studies (9/12): the probability of cost-effectiveness ranged from 35-99.5 percent. All studies had limitations and demonstrated uncertainty (particularly related to incremental costs). CONCLUSIONS: Most studies concluded psychological interventions for schizophrenia/BD are cost-effective, including CBT, although there was notable uncertainty. Heterogeneity across studies makes it difficult to reach strong conclusions. There is a particular need for more evidence in the population with BD and for longer-term evidence across both populations.
Authors: Eoin J Killackey; Henry J Jackson; John Gleeson; Ian B Hickie; Patrick D McGorry Journal: Aust N Z J Psychiatry Date: 2006 Nov-Dec Impact factor: 5.744
Authors: Gillian Haddock; Christine Barrowclough; Nicholas Tarrier; Jan Moring; Robert O'Brien; Nichola Schofield; Joanne Quinn; Steven Palmer; Linda Davies; Ian Lowens; John McGovern; Shôn Lewis Journal: Br J Psychiatry Date: 2003-11 Impact factor: 9.319
Authors: Leslie A Lenert; Ann P Sturley; Mark H Rapaport; Shannon Chavez; Penny E Mohr; Marcia Rupnow Journal: Schizophr Res Date: 2004-11-01 Impact factor: 4.939
Authors: Gemma E Shields; Deborah Buck; Filippo Varese; Alison R Yung; Andrew Thompson; Nusrat Husain; Matthew R Broome; Rachel Upthegrove; Rory Byrne; Linda M Davies Journal: BMC Psychiatry Date: 2022-02-17 Impact factor: 3.630